FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	OVAL				
	OMB Number:	3235-0287				
l	Estimated average burd	en				
l	hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SULLIVAN LOUIS W						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]										Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)							3. Date of Earliest Transaction (Month/Day/Year) 05/23/2013										or (give title)	10% Owles Other (sp below)			
Street) ROCKVILLE MD 20850 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Noi	າ-Deriv	ative	e Se	curitie	s Ac	cqui	ired, D	isp	osed c	of, or E	ene	ficial	y Owne	d				
1. Title of Security (Instr. 3) 2. Transa Date (Month/E						ear)	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transact Code (In 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				Benefic Owned	es ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
									-	Code	v	Amount	(A (D	or	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock ⁽¹⁾ 05/23/					3/201	2013				A		3,600		A	\$ <mark>0</mark>	14,400 ⁽²⁾			D		
		1	able II -				urities s, warr									Owned			,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. B)		5. Num of Deriva Securi Acquir (A) or Dispos of (D) (Instr. and 5)	tive ties ed sed	6. Date Exercisal Expiration Date (Month/Day/Year				Amoun Securit Underly Derivat	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisable	Ex Da	piration te	Title	or Nu of	umber						
Director stock option (right to buy)	\$14.25	05/23/2013			A		7,200			(3)	05/	/22/2020	Commo Stock	n 7	,200	\$0	7,200)	D		

Explanation of Responses:

- 1. Consists of restricted stock units granted under the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- 2. These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company or, if the Company's Annual Meeting of Stockholders occurs prior to such date for any year, on the day prior to such year's Annual Meeting of Stockholders. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 3. The option will vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company or, if the Company's Annual Meeting of Stockholders occurs prior to such date for any year, on the day prior to such year's Annual Meeting of Stockholders.

Remarks:

/s/Michael R. Darling, 05/24/2013 attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.